The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma

Oncotarget

Volumn 6, Issue 27, 2015, Pages 23609-23630

  Fionda, Cinzia ^a   Abruzzese, Maria Pia ^a   Zingoni, Alessandra ^a   Cecere, Francesca ^a   Vulpis, Elisabetta ^a   Peruzzi, Giovanna ^b   Soriani, Alessandra ^a   Molfetta, Rosa ^a   Paolini, Rossella ^a   Ricciardi, Maria Rosaria ^b   Petrucci, Maria Teresa ^b   Santoni, Angela ^a,c   Cippitelli, Marco ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c IRCCS NEUROMED   (Italy)

Author keywords

DNAM 1Ls; IMiDs; Multiple myeloma; Natural killer; NKG2DLs

Indexed keywords

CEREBLON; IKAROS TRANSCRIPTION FACTOR; IKAROS TRANSCRIPTION FACTOR 1; IKAROS TRANSCRIPTION FACTOR 3; IKAROS TRANSCRIPTION FACTOR 4; LENALIDOMIDE; NATURAL KILLER CELL RECEPTOR NKG2D; PEPTIDES AND PROTEINS; POMALIDOMIDE; PROTEIN DNAM1; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; ANGIOGENESIS INHIBITOR; CD226 ANTIGEN; HLA ANTIGEN CLASS 1; IKZF1 PROTEIN, HUMAN; IKZF3 PROTEIN, HUMAN; IMMUNOLOGIC FACTOR; INTERFERON REGULATORY FACTOR; INTERFERON REGULATORY FACTOR-4; KLRK1 PROTEIN, HUMAN; LIGAND; MHC CLASS I-RELATED CHAIN A; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K; POLIOVIRUS RECEPTOR; T LYMPHOCYTE ANTIGEN; THALIDOMIDE; VIRUS RECEPTOR;

ADULT; AGED; ARTICLE; CD155 GENE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG RECEPTOR BINDING; DRUG TARGETING; ENZYME ACTIVATION; FEMALE; GENE CONTROL; HUMAN; HUMAN CELL; MALE; MICA GENE; MIDDLE AGED; MULTIPLE MYELOMA; NATURAL KILLER CELL; PROTEIN EXPRESSION; PVR GENE; REPRESSOR GENE; UPREGULATION; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; DRUG EFFECTS; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PATHOLOGY; PROMOTER REGION; TUMOR CELL LINE;

AGED; ANGIOGENESIS INHIBITORS; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; CELL LINE, TUMOR; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IKAROS TRANSCRIPTION FACTOR; IMMUNOLOGIC FACTORS; INTERFERON REGULATORY FACTORS; KILLER CELLS, NATURAL; LIGANDS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; PROMOTER REGIONS, GENETIC; RECEPTORS, VIRUS; THALIDOMIDE;

EID: 84943409539     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4603     Document Type: Article

References (65)

1. Kyle RA, Rajkumar SV. Multiple myeloma. Blood 2008; 111:2962-2972.
2. Mahindra A, Laubach J, Raje N, Munshi N, Richardson PG, Anderson K. Latest advances and current challenges in the treatment of multiple myeloma. Nat.Rev.Clin.Oncol. 2012; 9:135-143.
3. Cook G, Campbell JD. Immune regulation in multiple myeloma:the host-tumour conflict. Blood Rev. 1999; 13:151-162.
4. Jinushi M, Vanneman M, Munshi NC, Tai YT, Prabhala RH, Ritz J, Neuberg D, Anderson KC, Carrasco DR, Dranoff G. MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc.Natl.Acad.Sci.U.S.A 2008;105:1285-1290.
5. Viel S, Charrier E, Marcais A, Rouzaire P, Bienvenu J, Karlin L, Salles G, Walzer T. Monitoring NK cell activity in patients with hematological malignancies. Oncoimmunology. 2013;2:e26011.
6. Cerwenka A, Lanier LL. Ligands for natural killer cell receptors:redundancy or specificity. Immunol.Rev. 2001; 181:158-169.
7. Lanier LL. NK cell recognition. Annu.Rev.Immunol 2005; 23:225-274.
8. Raulet DH, Gasser S, Gowen BG, Deng W, Jung H. Regulation of ligands for the NKG2D activating receptor. Annu.Rev.Immunol. 2013;31:413-441.
9. Bedel R, Thiery-Vuillemin A, Grandclement C, Balland J, Remy-Martin JP, Kantelip B, Pallandre JR, Pivot X, Ferrand C, Tiberghien P, Borg C. Novel role for STAT3 in transcriptional regulation of NK immune cell targeting receptor MICA on cancer cells. Cancer Res. 2011;71:1615-1626.
10. El-Gazzar A, Groh V, Spies T. Immunobiology and conflicting roles of the human NKG2D lymphocyte receptor and its ligands in cancer. J.Immunol. 2013;191:1509-1515.
11. Fernandez-Messina L, Ashiru O, Boutet P, AgueraGonzalez S, Skepper JN, Reyburn HT, Vales-Gomez M. Differential mechanisms of shedding of the glycosylphosphatidylinositol (GPI)-anchored NKG2D ligands. J.Biol.Chem. 2010;285:8543-8551.
12. Ashiru O, Boutet P, Fernandez-Messina L, AgueraGonzalez S, Skepper JN, Vales-Gomez M, Reyburn HT. Natural killer cell cytotoxicity is suppressed by exposure to the human NKG2D ligand MICA*008 that is shed by tumor cells in exosomes. Cancer Res. 2010;70:481-489.
13. Fuchs A, Colonna M. The role of NK cell recognition of nectin and nectin-like proteins in tumor immunosurveillance. Semin.Cancer Biol. 2006;16:359-366.
14. Carbone E, Neri P, Mesuraca M, Fulciniti MT, Otsuki T, Pende D, Groh V, Spies T, Pollio G, Cosman D, Catalano L, Tassone P, Rotoli B, Venuta S. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood 2005;105:251-258.
15. El-Sherbiny YM, Meade JL, Holmes TD, McGonagle D, Mackie SL, Morgan AW, Cook G, Feyler S, Richards SJ, Davies FE, Morgan GJ, Cook GP. The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cellmediated killing of myeloma cells. Cancer Res. 2007; 67:8444-8449.
16. Soriani A, Zingoni A, Cerboni C, Iannitto ML, Ricciardi MR, Di G, V, Cippitelli M, Fionda C, Petrucci MT, Guarini A, Foa R, Santoni A. ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood 2009;113:3503-3511.
17. Fionda C, Soriani A, Malgarini G, Iannitto ML, Santoni A, Cippitelli M. Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation. J.Immunol. 2009;183:4385-4394.
18. Guillerey C, Ferrari de AL, Vuckovic S, Miles K, Ngiow SF, Yong MC, Teng MW, Colonna M, Ritchie DS, Chesi M, Bergsagel PL, Hill GR, MJ SM, Martinet L. Immunosurveillance and therapy of multiple myeloma are CD226 dependent. J.Clin.Invest 2015.
19. Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT, Lin B, Podar K, Gupta D, Chauhan D, Treon SP, Richardson PG, Schlossman RL, Morgan GJ, Muller GW, Stirling DI, Anderson KC. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001;98:210-216.
20. Zhu D, Corral LG, Fleming YW, Stein B. Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol. Immunother. 2008;57:1849-1859.
21. Shortt J, Hsu AK, Johnstone RW. Thalidomide-analogue biology:immunological, molecular and epigenetic targets in cancer therapy. Oncogene 2013;32:4191-4202.
22. Semeraro M, Vacchelli E, Eggermont A, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch:Lenalidomidebased immunochemotherapy. Oncoimmunology. 2013; 2:e26494.
23. Lioznov M, El-Cheikh J, Jr., Hoffmann F, Hildebrandt Y, Ayuk F, Wolschke C, Atanackovic D, Schilling G, Badbaran A, Bacher U, Fehse B, Zander AR, Blaise D, Mohty M, Kroger N. Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells. Bone Marrow Transplant. 2010;45:349-353.
24. Hayashi T, Hideshima T, Akiyama M, Podar K, Yasui H, Raje N, Kumar S, Chauhan D, Treon SP, Richardson P, Anderson KC. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br.J.Haematol. 2005;128:192-203.
25. Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D, Schafer P, Bartlett JB. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin. Cancer Res. 2008;14:4650-4657.
26. Benson DM, Jr., Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, Baiocchi RA, Zhang J, Yu J, Smith MK, Greenfield CN, Porcu P, Devine SM, Rotem-Yehudar R, Lozanski G, Byrd JC, Caligiuri MA. The PD-1/PDL1 axis modulates the natural killer cell versus multiple myeloma effect:a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 2010;116:2286-2294.
27. Fionda C, Malgarini G, Soriani A, Zingoni A, Cecere F, Iannitto ML, Ricciardi MR, Federico V, Petrucci MT, Santoni A, Cippitelli M. Inhibition of glycogen synthase kinase-3 increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells:role of STAT3. J.Immunol. 2013;190:6662-6672.
28. Benson DM, Jr., Bakan CE, Zhang S, Collins SM, Liang J, Srivastava S, Hofmeister CC, Efebera Y, Andre P, Romagne F, Blery M, Bonnafous C, Zhang J, Clever D, Caligiuri MA, Farag SS. IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. Blood 2011;118:6387-6391.
29. Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, Yamaguchi Y, Handa H. Identification of a primary target of thalidomide teratogenicity. Science 2010;327:1345-1350.
30. Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J, Karasawa S, Carmel G, Jackson P, Abbasian M, Mahmoudi A, Cathers B, Rychak E, Gaidarova S, Chen R, Schafer PH, Handa H, Daniel TO, Evans JF, Chopra R. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 2012;26:2326-2335.
31. Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Van WS, Chang XB, Bjorklund CC, Fonseca R, Bergsagel PL, Orlowski RZ, Stewart AK. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 2011;118:4771-4779.
32. Chamberlain PP, Lopez-Girona A, Miller K, Carmel G, Pagarigan B, Chie-Leon B, Rychak E, Corral LG, Ren YJ, Wang M, Riley M, Delker SL, Ito T, Ando H, Mori T, Hirano Y, Handa H, Hakoshima T, Daniel TO, Cathers BE. Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs. Nat.Struct.Mol.Biol. 2014;21:803-809.
33. Fischer ES, Bohm K, Lydeard JR, Yang H, Stadler MB, Cavadini S, Nagel J, Serluca F, Acker V, Lingaraju GM, Tichkule RB, Schebesta M, Forrester WC, Schirle M, Hassiepen U, Ottl J, Hild M, Beckwith RE, Harper JW, Jenkins JL, Thoma NH. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature 2014; 512:49-53.
34. Lu G, Middleton RE, Sun H, Naniong M, Ott CJ, Mitsiades CS, Wong KK, Bradner JE, Kaelin WG, Jr. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 2014;343:305-309.
35. Kronke J, Udeshi ND, Narla A, Grauman P, Hurst SN, McConkey M, Svinkina T, Heckl D, Comer E, Li X, Ciarlo C, Hartman E, Munshi N, Schenone M, Schreiber SL, Carr SA, Ebert BL. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 2014;343:301-305.
36. Zhu YX, Braggio E, Shi CX, Kortuem KM, Bruins LA, Schmidt JE, Chang XB, Langlais P, Luo M, Jedlowski P, LaPlant B, Laumann K, Fonseca R, Bergsagel PL, Mikhael J, Lacy M, Champion MD, Stewart AK. Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma. Blood 2014; 124:536-545.
37. Orozco CA, Acevedo A, Cortina L, Cuellar GE, Duarte M, Martin L, Mesa NM, Munoz J, Portilla CA, Quijano SM, Quintero G, Rodriguez M, Saavedra CE, Groot H, Torres MM, Lopez-Segura V. The combined expression patterns of Ikaros isoforms characterize different hematological tumor subtypes. PLoS.One. 2013;8:e82411.
38. Gandhi AK, Kang J, Havens CG, Conklin T, Ning Y, Wu L, Ito T, Ando H, Waldman MF, Thakurta A, Klippel A, Handa H, Daniel TO, Schafer PH, Chopra R. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.). Br.J.Haematol. 2014;164:811-821.
39. Shaffer AL, Emre NC, Romesser PB, Staudt LM. IRF4: Immunity. Malignancy! Therapy? Clin.Cancer Res. 2009; 15:2954-2961.
40. Shaffer AL, Emre NC, Lamy L, Ngo VN, Wright G, Xiao W, Powell J, Dave S, Yu X, Zhao H, Zeng Y, Chen B, Epstein J, Staudt LM. IRF4 addiction in multiple myeloma. Nature 2008;454:226-231.
41. Fionda C, Soriani A, Malgarini G, Iannitto ML, Santoni A, Cippitelli M. Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation. J Immunol 2009;183:4385-4394.
42. Bryceson YT, March ME, Barber DF, Ljunggren HG, Long EO. Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells. J Exp. Med. 2005;202:1001-1012.
43. Sun L, Liu A, Georgopoulos K. Zinc finger-mediated protein interactions modulate Ikaros activity, a molecular control of lymphocyte development. EMBO J. 1996; 15:5358-5369.
44. Suzuki K, Ono R, Ohishi K, Masuya M, Kataoka I, Liu B, Nakamori Y, Ino K, Monma F, Hamada H, Kitamura T, Katayama N, Nosaka T. IKAROS isoform 6 enhances BCR-ABL1-mediated proliferation of human CD34+ hematopoietic cells on stromal cells. Int.J.Oncol. 2012; 40:53-62.
45. Lopez-Girona A, Heintel D, Zhang LH, Mendy D, Gaidarova S, Brady H, Bartlett JB, Schafer PH, Schreder M, Bolomsky A, Hilgarth B, Zojer N, Gisslinger H, Ludwig H, Daniel T, Jager U, Chopra R. Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response. Br.J.Haematol. 2011;154:325-336.
46. Sciammas R, Shaffer AL, Schatz JH, Zhao H, Staudt LM, Singh H. Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation. Immunity. 2006;25:225-236.
47. Ma S, Pathak S, Trinh L, Lu R. Interferon regulatory factors 4 and 8 induce the expression of Ikaros and Aiolos to down-regulate pre-B-cell receptor and promote cellcycle withdrawal in pre-B-cell development. Blood 2008; 111:1396-1403.
48. Holstein SA. The Evolving Tale of Immunomodulatory Drugs and Cereblon. Clin.Pharmacol.Ther. 2014.
49. Chang X, Zhu Y, Shi C, Stewart AK. Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma. Acta Biochim.Biophys.Sin.(Shanghai) 2014;46:240-253.
50. Venkataraman GM, Suciu D, Groh V, Boss JM, Spies T. Promoter region architecture and transcriptional regulation of the genes for the MHC class I-related chain A and B ligands of NKG2D. J Immunol 2007;178:961-969.
51. Gorgun G, Calabrese E, Soydan E, Hideshima T, Perrone G, Bandi M, Cirstea D, Santo L, Hu Y, Tai YT, Nahar S, Mimura N, Fabre C, Raje N, Munshi N, Richardson P, Anderson KC. Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood 2010; 116:3227-3237.
52. Escoubet-Lozach L, Lin IL, Jensen-Pergakes K, Brady HA, Gandhi AK, Schafer PH, Muller GW, Worland PJ, Chan KW, Verhelle D. Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res. 2009;69:7347-7356.
53. Armeanu S, Bitzer M, Lauer UM, Venturelli S, Pathil A, Krusch M, Kaiser S, Jobst J, Smirnow I, Wagner A, Steinle A, Salih HR. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res. 2005;65:6321-6329.
54. Chavez-Blanco A, Cruz-Hernandez E, Dominguez GI, Rodriguez-Cortez O, Alatorre B, Perez-Cardenas E, Chacon-Salinas R, Trejo-Becerril C, Taja-Chayeb L, Trujillo JE, Contreras-Paredes A, Duenas-Gonzalez A. Upregulation of NKG2D ligands and enhanced natural killer cell cytotoxicity by hydralazine and valproate. Int.J.Oncol. 2011;39:1491-1499.
55. Diermayr S, Himmelreich H, Durovic B, MathysSchneeberger A, Siegler U, Langenkamp U, Hofsteenge J, Gratwohl A, Tichelli A, Paluszewska M, WiktorJedrzejczak W, Kalberer CP, Wodnar-Filipowicz A. NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities. Blood 2008;111:1428-1436.
56. Wu X, Tao Y, Hou J, Meng X, Shi J. Valproic acid upregulates NKG2D ligand expression through an ERKdependent mechanism and potentially enhances NK cellmediated lysis of myeloma. Neoplasia. 2012;14:1178-1189.
57. Schmudde M, Braun A, Pende D, Sonnemann J, Klier U, Beck JF, Moretta L, Broker BM. Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells. Cancer Lett. 2008;272:110-121.
58. Brown KE, Guest SS, Smale ST, Hahm K, Merkenschlager M, Fisher AG. Association of transcriptionally silent genes with Ikaros complexes at centromeric heterochromatin. Cell 1997;91:845-854.
59. Koipally J, Georgopoulos K. Ikaros interactions with CtBP reveal a repression mechanism that is independent of histone deacetylase activity. J.Biol.Chem. 2000;275:19594-19602.
60. Koipally J, Renold A, Kim J, Georgopoulos K. Repression by Ikaros and Aiolos is mediated through histone deacetylase complexes. EMBO J. 1999;18:3090-3100.
61. Marecki S, Fenton MJ. The role of IRF-4 in transcriptional regulation. J.Interferon Cytokine Res. 2002;22:121-133.
62. Soriani A, Iannitto ML, Ricci B, Fionda C, Malgarini G, Morrone S, Peruzzi G, Ricciardi MR, Petrucci MT, Cippitelli M, Santoni A. Reactive oxygen species-and DNA damage response-dependent NK cell activating ligand upregulation occurs at transcriptional levels and requires the transcriptional factor E2F1. J.Immunol. 2014;193:950-960.
63. Yoshida K, Yamamoto K, Kohno T, Hironaka N, Yasui K, Kojima C, Mukae H, Kadota J, Suzuki S, Honma K, Kohno S, Matsuyama T. Active repression of IFN regulatory factor-1-mediated transactivation by IFN regulatory factor-4. Int.Immunol. 2005;17:1463-1471.
64. Solecki D, Schwarz S, Wimmer E, Lipp M, Bernhardt G. The promoters for human and monkey poliovirus receptors. Requirements for basic and cell type-specific activity. J.Biol.Chem. 1997;272:5579-5586.
65. Fionda C, Nappi F, Piccoli M, Frati L, Santoni A, Cippitelli M. Inhibition of trail gene expression by cyclopentenonic prostaglandin 15-deoxy-delta12,14-prostaglandin J2 in T lymphocytes. Mol.Pharmacol. 2007;72:1246-1257.